Last reviewed · How we verify
Clopidogrel and Aspirin
Clopidogrel and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.
Clopidogrel and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of cardiovascular events in patients with acute myocardial infarction or stroke.
At a glance
| Generic name | Clopidogrel and Aspirin |
|---|---|
| Also known as | Clopidogrel: Plavix, Aspirin: Astrix |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Dual antiplatelet agent (combination therapy) |
| Target | P2Y12 receptor (clopidogrel); COX-1 (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet activation, while aspirin irreversibly inhibits cyclooxygenase (COX) to prevent thromboxane A2 synthesis. Together, they provide complementary antiplatelet effects by targeting distinct mechanisms of platelet aggregation, resulting in more potent anticoagulation than either agent alone.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Secondary prevention of cardiovascular events in patients with acute myocardial infarction or stroke
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Gastrointestinal hemorrhage
- Intracranial hemorrhage
- Rash
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel and Aspirin CI brief — competitive landscape report
- Clopidogrel and Aspirin updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI